Journal Club Cancer Immunotherapy

Organisation

We offer a weekly Journal Club focusing on "Cancer Immunotherapy" which takes place on Mondays at 9.00 a.m. with more than 30 participants from different departments and research programs of the DKFZ and NCT. The seminar participants are Master and PhD students, postdocs and group leaders. Our aim is to critically review the newest literature in the field of cancer immunotherapy.

 

Each participant presents a paper approximately every 8 months in a 30 to 40 min Powerpoint presentation. The publication is then discussed by all attendies. Since mid of 2015 more than 160 papers have been presented..

Due to the Corona virus situation, the journal club is presently completely virtually given as video conference with a shared presentation. Discussion is possible. 

If you are interested to join, please contact S. Eichmüller, who is organizing this seminar. Participation can be confirmed for the PhD program.

list of papers presented so far can be found here (pdf-file; updated 2020-05-06).

 

Most recent papers presented

  • Mills et al., 2019. Cell Reports. Stereotactic Body Radiation and Interleukin-12 Combination Therapy Eradicates Pancreatic Tumors by Repolarizing the Immune Microenvironment
  • Li et al., 2020. Can Imm Res. Tumor cell–intrinsic USP22 suppresses antitumor immunity in pancreatic cancer
  • van den Eynden et al., 2019. Nature Genetics. Lack of detectable neoantigen depletion signals in the untreated cancer genome
  • Gauthier et al., 2019. Cell. Multifunctional Natural Killer Cell Engagers Targeting NKp46 Trigger Protective Tumor Immunity
  • Crowther et al., 2020. Nature Immunol. Genome-wide CRISPR–Cas9 screening reveals ubiquitous T cell cancer targeting via the monomorphic MHC class I-related protein MR1
  • Zhang et al., 2020. Mol Therapy. oHSV2 Can Target Murine Colon Carcinoma by Altering the Immune Status of the Tumor Microenvironment and Inducing Antitumor Immunity
  • Stromnes et al., 2019. Can Imm Res. Differential Effects of Depleting versus Programming Tumor-Associated Macrophages on Engineered T Cells in Pancreatic Ductal Adenocarcinoma
  • Yu et al., 2020. Nature Comm. CD73 on cancer-associated fibroblasts enhanced by the A2B-mediated feedforward circuit enforces an immune checkpoint
  • Arina et al., 2019. Nature Comm. Tumor-reprogrammed resident T cells resist radiation to control tumors
  • Wang et al., 2020. Nature Comm. An engineered oncolytic virus expressing PD-L1 inhibitors activates tumor neoantigen-specific T cell responses
  • Mayoux et al., 2020. Sci Transl Med. Dendritic cells dictate responses to PD-L1 blockade cancer immunotherapy

to top
powered by webEdition CMS